ATPW
KPTI icon

Ashton Thomas Private Wealth’s Karyopharm Therapeutics KPTI Stock Holding History

Ashton Thomas Private Wealth’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,067
Closed -$62.2K – 589
2023
Q1 		$62.2K Buy
1,067
+100
+10% +$4.94K 0.01% 491
2022
Q4 		$49.3K Buy
+967
New +$67K ﹤0.01% 469

Other funds holding KPTI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
ECM
ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Ashton Thomas Private Wealth's KPTI Position: Q2 2023 in Review

Ashton Thomas Private Wealth sold out of Karyopharm Therapeutics (KPTI) in Q2 2023, closing a stake of 1,067 shares — an estimated $62.2K sold.

Ashton Thomas Private Wealth first reported a position in KPTI in Q4 2022 and held it in 2 quarters. The position peaked at $62.2K in Q1 2023. 137 funds tracked by Wall St. Rank hold KPTI as of Q2 2023.

  • Ashton Thomas Private Wealth reported no remaining Karyopharm Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Ashton Thomas Private Wealth sold 1,067 Karyopharm Therapeutics shares in Q2 2023, an estimated $62.2K.
  • Ashton Thomas Private Wealth first reported a position in Karyopharm Therapeutics in Q4 2022 and held it in 2 quarters.
  • Ashton Thomas Private Wealth's Karyopharm Therapeutics position peaked at $62.2K in Q1 2023.
  • 137 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2023.

Based on Ashton Thomas Private Wealth's 13F filing for Q2 2023, filed 23 Apr 2024.